Canada Markets closed

Hemostemix Inc. (HEM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.16000.0000 (0.00%)
At close: 12:21PM EST
Full screen
Previous Close0.1600
Open0.1600
Bid0.1600 x 0
Ask0.1650 x 0
Day's Range0.1600 - 0.1600
52 Week Range0.1150 - 0.4200
Volume10,100
Avg. Volume84,108
Market Cap9.464M
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-0.2410
Earnings DateSept 26, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.96
  • Newsfile

    Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview

    Calgary, Alberta--(Newsfile Corp. - November 17, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to thank six-time Grammy Award Winner, Mr. Howie Lindeman, for his ACP-01 testimonial interview (https://www.youtube.com/watch?v=KTuq3Oy7WU0) now available on YouTube.Cannot view this video? Visit:https://www.youtube.com/watch?v=KTuq3Oy7WU0Mr. Howard "Howie" Lindeman started at The Record Plant recording studios NYC in 1974. His career as a Pr

  • Newsfile

    Hemostemix Announces Advancements in Its Automation of Production

    Calgary, Alberta--(Newsfile Corp. - November 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the continued evolution of its patented Automated Cell Therapy System (ACTS). The Hemostemix ACTS is designed to scale our autologous stem cell therapy processes by leveraging robotic-material-handling and parallel-processing efficiencies, duplicating our manual methods of angiogenic cell precursor (ACP-01) production. ACTS will sc

  • Newsfile

    Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials

    Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. Dr. Giannetti and Dr. Cecere will assist Hemostemix with financing introductions and due diligence responses; help position ACP-01 as a candidate to be the first-to-patient autologous stem cell treatment of heart disease; design